Intratumoral CAN1012(selective TLR7 Agonist) in Subjects with Solid Tumors

NCT05580991 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor

Interventions

DRUG: CAN1012

Sponsor

Canwell Biotech Limited